Production (Stage)
Krystal Biotech, Inc.
KRYS
$136.94
$4.323.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.43% | 67.33% | 74.57% | 1,570.49% | -89.28% |
| Total Depreciation and Amortization | 47.03% | -13.99% | -64.45% | 100.54% | -33.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.23% | -2.96% | 7.33% | 52.51% | -11.87% |
| Change in Net Operating Assets | -227.42% | -131.11% | 154.65% | -628.38% | 124.21% |
| Cash from Operations | -41.39% | -10.22% | 1,512.12% | -126.23% | 319.69% |
| Capital Expenditure | -674.53% | 23.42% | 7.52% | 10.24% | 31.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 41.47% | -149.31% | -82.65% | 26.29% | -197.37% |
| Cash from Investing | 34.63% | -144.05% | -77.38% | 25.51% | -155.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -39.79% | -27.85% | -68.37% | -33.38% | 509.74% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -613.43% | -27.85% | -68.37% | 0.52% | 304.09% |
| Foreign Exchange rate Adjustments | 128.79% | -307.69% | 184.87% | -280.21% | 233.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -24.03% | -203.27% | 313.16% | -2,049.85% | 104.55% |